Objective-To evaluate the effectiveness of biochemical screening of 
Introduction
Trisomy 21 (Down's syndrome) is the commonest human chromosomal abnormality, occurring in about one in 700 babies.' Down's syndrome can be detected during pregnancy by determining the karyotype of fetal cells, but the limited resources available for this test and the morbidity associated with sampling fetal tissue restrict the procedure to women who, on the grounds of age or genetic history, are thought to be at highest risk.
The risk ofconceiving a child with Down's syndrome increases sharply with age, and at present women aged 36 years at the estimated date of delivery are widely regarded as having a right to be offered karyotype determination.' Only 30% of pregnancies associated with Down's syndrome occur in women over 35 years old, however, and in practice about 15% of cases are detected antenatally.3 In women with pregnancies associated with Down's syndrome mean concentrations of a fetoprotein, chorionic gonadotrophin, and unconjugated oestriol are abnormal for gestational age. 46 Wald et al proposed that by modifying a woman's age related risk according to the concentrations of these biochemical markers the same number of karyotype analyses would be used more rationally, increasing threefold the proportion of affected pregnancies detected in the second trimester.
I They speculated that the greatest improvement in detection rate would be achieved by using cc fetoprotein and chorionic gonadotrophin assays. We conducted a study to investigate this proposition.
Subjects and methods
We studied 3436 women who had been screened for neural tube defects in the second trimester ofpregnancy during November 1988 to March 1990. This represented 58% ofthe total screened obstetric population in Tayside. All the women had had their pregnancies dated by ultrasonography. The serum samples obtained at screening were analysed for a fetoprotein and chorionic gonadotrophin blind to pregnancy outcome after the termination of the pregnancy or birth of the baby.
Concentrations of a fetoprotein were measured by an immunoradiometric assay,7 which was modified to allow magnetic separation. 7 The between assay precision (coefficients of variation) during the study ranged from 10% at 8 kU/I to 5% between 30 and 500 kU/l. Chorionic gonadotrophin was measured by a radioimmunoassay8 modified for routine use on serum specimens taken in the second trimester. The between assay precision ranged from 10% at 3 kU/l to less than 6% between 9 and 60 kU/l. Reagents for these assays were produced on a large scale for the Scottish Health Service and are available from our laboratory and from the Scottish Antibody Production Unit at Law Hospital, Lanarkshire If data from the three affected pregnancies recorded during April to December 1990 are included screening on the basis of individual risk would have detected eight of 11 (73%) affected pregnancies. A similar degree of success has been reported in retrospective analyses of data from selected specimens from affected and unaffected pregnancies.2"3 Macri et al suggested that free P chorionic gonadotrophin may be a better marker than the intact molecule,'2 although their detection rate was identical with ours.
The age distribution ofwomen who would have been offered screening on the basis of individual risk during the study period matched the expected distribution 6f women having babies with Down's syndrome more closely than did the age distribution of women who had karyotype analysis (fig 2) . Screening based on risk analysis would have given a false negative rate of 38% (27% with the updated figures for 1990), which compares with a rate of 88% (82% updated) from screening based on maternal age and genetic history.
Unless resources were increased by 50% performing amniocentesis and karyotype determination on the basis of calculated risk would be possible only if the automatic right of women aged over 35 to these procedures were removed.2 It is therefore important to be able to reassure women over 35, who are currently almost guaranteed that a fetus with Down's syndrome BMJ VOLUME 303will be detected, that the new test has a similar probability of success. The distribution of medians and individual risk estimates in our study suggests that there is a high probability that women older than 35 with affected pregnancies would be offered screening. This was also found in a recent study by Mancini et 
Introduction
Several studies have described a J-shaped association between intake of alcohol and risk of cardiovascular disease, with the lowest risk among light drinkers and higher risks among non-drinkers and heavy drinkers. ' 
